Skip to main content

High rate of hypoglycemia in diabetic pregnant women on use of glyburide

Background

The prevalence of gestational diabetes (GD) in Brazil can exceed 18% when applied the current WHO diagnostic criteria. The importance of the GD treatment in reducing severe outcomes of perinatal maternal morbidity and has been shown in randomized clinical trials. Therapeutic options for the GD have included oral antidiabetic agents glibenclamide (GB) and metformin (MF) showed Results of safety and efficacy similar to insulin.

Objective

To analyze the effects of the use of GB and MF in the treatment of GD in pregnant women at a specialized clinic in HCPA in a randomized open-label study.

Materials and methods

Eighty-one women diagnosed with GD and drug treatment indication were randomized. The initial dose of GB was 2.5 mg/day with an increase of 2.5 mg next week and new increments of 5 mg/week to achieve glycemic targets or maximum dose (20mg/day); MF is an initial dose of 500mg to 500mg increments every 3 days to obtain the target or maximum dose of 2.5 g/day.

Results

Thirty-six patients were randomized to the MT group and 45 for the GB group. The slurry treatment rate were 22.9% and 54.5%, respectively MP and GB group (p=0.006). Reasons for discontinuation of medications is hypoglycemia: 2.9% and 38.6% (p <0.001), respectively MF and GB group; not glycemic compensation: 2.9% and 13.6% (p=0.095), respectively MF and G groups); and gastric intolerance: 17.1% and 2.3% (p=0.021) respectively MF group and GB.

Conclusion

Current evidence suggests that oral anti-diabetics are safe and effective for glycemic control in GD. This study was prematurely terminated by the high incidence of hypoglycemia in the GB group, considered ethically unacceptable by an independent review committee. MF was well tolerated and showed up as the first oral option in drug treatment of hyperglycemia in pregnancy.

Figure 1
figure1

Patients' results medications.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Vanessa Krebs Genro.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

De Bacco, G., Genro, V.K., Salazer, C.C. et al. High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetol Metab Syndr 7, A85 (2015). https://doi.org/10.1186/1758-5996-7-S1-A85

Download citation

Keywords

  • Pregnant Woman
  • Metformin
  • Hyperglycemia
  • Hypoglycemia
  • Maximum Dose